EE200300464A - Protsess asetidinoonvaheühendite valmistamiseks ja asetidinoonvaheühend - Google Patents

Protsess asetidinoonvaheühendite valmistamiseks ja asetidinoonvaheühend

Info

Publication number: EE200300464A
Authority: EE; Estonia
Prior art keywords: azetidinone; preparation; intermediates; compound; atheroschlerosis
Prior art date: 2001-03-28

Application number

EEP200300464A

Other languages

English (en)

Inventor

Fu Xiaoyong

L. Mcallister Timothy

K. Thiruvengadam T.

Tann Chou-Hong

Original Assignee

Schering Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-28

Filing date

2002-03-25

Publication date

2003-12-15

2002-03-25 Application filed by Schering Corporation filed Critical Schering Corporation

2003-12-15 Publication of EE200300464A publication Critical patent/EE200300464A/et

2011-08-15 Publication of EE05453B1 publication Critical patent/EE05453B1/et

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Urology & Nephrology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Vascular Medicine (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Catalysts (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

EEP200300464A 2001-03-28 2002-03-25 Protsess asetidinoonvahehendite valmistamiseks EE05453B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27928801P	2001-03-28	2001-03-28
PCT/US2002/009123 WO2002079174A2 (en)	2001-03-28	2002-03-25	Enantioselective synthesis of azetidinone intermediate compounds

Publications (2)

Publication Number	Publication Date
EE200300464A true EE200300464A (et)	2003-12-15
EE05453B1 EE05453B1 (et)	2011-08-15

Family

ID=23068350

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300464A EE05453B1 (et)	2001-03-28	2002-03-25	Protsess asetidinoonvahehendite valmistamiseks

Country Status (28)

Country	Link
US (1)	US6627757B2 (et)
EP (1)	EP1373230B1 (et)
JP (1)	JP4145663B2 (et)
KR (1)	KR100590342B1 (et)
CN (1)	CN1275949C (et)
AT (1)	ATE305459T1 (et)
AU (1)	AU2002258605B2 (et)
BG (1)	BG66189B1 (et)
BR (1)	BRPI0208384B1 (et)
CA (1)	CA2442219C (et)
CZ (1)	CZ304929B6 (et)
DE (1)	DE60206365T2 (et)
DK (1)	DK1373230T3 (et)
EA (1)	EA006898B1 (et)
EE (1)	EE05453B1 (et)
ES (1)	ES2245733T3 (et)
HR (1)	HRP20030760B1 (et)
HU (1)	HU230229B1 (et)
IL (2)	IL157552A0 (et)
MX (1)	MXPA03008803A (et)
NZ (1)	NZ527852A (et)
PL (1)	PL205952B1 (et)
RS (1)	RS50386B (et)
SI (1)	SI1373230T1 (et)
SK (1)	SK287408B6 (et)
UA (1)	UA75644C2 (et)
WO (1)	WO2002079174A2 (et)
ZA (1)	ZA200306612B (et)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0215579D0 (en)	2002-07-05	2002-08-14	Astrazeneca Ab	Chemical compounds
US20040132058A1 (en)	2002-07-19	2004-07-08	Schering Corporation	NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en)	2002-07-19	2006-11-14	Schering Corporation	NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es)	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP1918000A2 (en)	2003-11-05	2008-05-07	Schering Corporation	Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7871998B2 (en)	2003-12-23	2011-01-18	Astrazeneca Ab	Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
MXPA06008124A (es) *	2004-01-16	2007-01-26	Merck & Co Inc	Npc1l1 (npc3) y metodos para identificar ligandos del mismo.
CA2581596A1 (en) *	2004-09-29	2006-04-13	Schering Corporation	Combinations of substituted azetidonones and cb1 antagonists
US7700597B2 (en)	2004-12-03	2010-04-20	Schering Corporation	Substituted piperazines as CB1 antagonists
US8308559B2 (en) *	2007-05-07	2012-11-13	Jay Chun	Paradise box gaming system
TW200726746A (en)	2005-05-06	2007-07-16	Microbia Inc	Processes for production of 4-biphenylylazetidin-2-ones
AU2006244125A1 (en) *	2005-05-09	2006-11-16	Microbia, Inc.	Organometal benzenephosphonate coupling agents
MX2007014172A (es) *	2005-05-11	2008-04-02	Microbia Inc	Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
US20090099355A1 (en) *	2005-05-25	2009-04-16	Microbia, Inc.	Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids
ATE450526T1 (de) *	2005-06-20	2009-12-15	Schering Corp	Als antagonisten von histamin h3 geeignete piperidinderivate
SA06270191B1 (ar)	2005-06-22	2010-03-29	استرازينيكا ايه بي	مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
KR20070063592A (ko) *	2005-09-08	2007-06-19	테바 파마슈티컬 인더스트리즈 리미티드	에제티밉의 합성을 위한 중간체인(3ｒ,4ｓ)-4-((4-벤질옥시)페닐)-1-(4-플루오로페닐)-3-((ｓ)-3-(4-플루오로페닐)-3-히드록시프로필)-2-아제티디논의제조 방법
HUP0501164A2 (en) *	2005-12-20	2007-07-30	Richter Gedeon Nyrt	New industrial process for the production of ezetimibe
BRPI0706623A2 (pt)	2006-01-18	2011-04-12	Schering Corp	moduladores de receptor canabinóide
CN101384532B (zh) *	2006-02-16	2013-01-02	寿制药株式会社	制造光学活性醇的方法
WO2007100807A2 (en)	2006-02-24	2007-09-07	Schering Corporation	Npc1l1 orthologues
AR060623A1 (es)	2006-04-27	2008-07-02	Astrazeneca Ab	Compuestos derivados de 2-azetidinona y un metodo de preparacion
EP2059241A1 (en) *	2006-09-05	2009-05-20	Schering Corporation	Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008130616A2 (en) *	2007-04-19	2008-10-30	Schering Corporation	Diaryl morpholines as cb1 modulators
US20090047716A1 (en) *	2007-06-07	2009-02-19	Nurit Perlman	Reduction processes for the preparation of ezetimibe
KR20100051625A (ko) *	2007-06-28	2010-05-17	인터벳 인터내셔널 비.브이.	Ｃｂ1 길항제로서의 치환된 피페라진
JP2010531874A (ja) *	2007-06-28	2010-09-30	インターベットインターナショナルベー．フェー．	Ｃｂ１アンタゴニストとしての置換ピペラジン
WO2009032264A1 (en) *	2007-08-30	2009-03-12	Teva Pharmaceutical Industries Ltd.	Processes for preparing intermediates of ezetimibe by microbial reduction
US20090312302A1 (en) *	2008-06-17	2009-12-17	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
US8273554B2 (en)	2008-08-29	2012-09-25	Codexis, Inc.	Ketoreductase polypeptides for the stereoselective production of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
CA2757722C (en)	2009-04-01	2018-05-22	Matrix Laboratories Ltd.	Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
EP2467473B1 (en)	2009-08-19	2016-03-23	Codexis, Inc.	Ketoreductase polypeptides for the preparation of phenylephrine
EP2566497B1 (en)	2010-05-04	2015-07-29	Codexis, Inc.	Biocatalysts for ezetimibe synthesis
WO2012155932A1 (en)	2011-05-17	2012-11-22	Pharmathen S.A.	Improved process for the preparation of ezetimibe
CN111518046B (zh) *	2020-06-04	2022-04-15	中山奕安泰医药科技有限公司	依泽替米贝中间体及依泽替米贝的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2046823A1 (de)	1970-09-23	1972-03-30	Farbwerke Hoechst AG vormals Meister Lucius & Brüning, 6000 Frankfurt	Neue Azetidinone-(2) und Verfahren zu deren Herstellung
JPS5628057A (en)	1979-08-13	1981-03-19	Isuzu Motors Ltd	Front cab suspension device for tiltable cab
DE3006193C2 (de)	1980-02-19	1984-04-12	Siemens AG, 1000 Berlin und 8000 München	Elektrische Anschlußverbindung der Elektroden eines Gasentladungs-Überspannungsableiters
US4680391A (en)	1983-12-01	1987-07-14	Merck & Co., Inc.	Substituted azetidinones as anti-inflammatory and antidegenerative agents
JPS61121479A (ja)	1984-11-19	1986-06-09	Mitsubishi Electric Corp	太陽電池素子
JPS61180212A (ja)	1985-02-06	1986-08-12	Asahi Optical Co Ltd	後絞り型写真レンズ
JPS62219681A (ja)	1986-03-20	1987-09-26	Toshiba Corp	光信号処理素子の基準光源
NZ222015A (en)	1986-10-03	1989-10-27	Lilly Co Eli	7-(meta-substituted phenylglycine)-1-carba-1-dethiacephalsporins and pharmaceutical compositions
US4803266A (en)	1986-10-17	1989-02-07	Taisho Pharmaceutical Co., Ltd.	3-Oxoalkylidene-2-azetidinone derivatives
EP0333268A1 (en)	1988-03-18	1989-09-20	Merck & Co. Inc.	Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
IL89835A0 (en)	1988-04-11	1989-12-15	Merck & Co Inc	Substituted azetidinones,their preparation and pharmaceutical compositions containing them
US4952689A (en)	1988-10-20	1990-08-28	Taisho Pharmaceutical Co., Ltd.	3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US4876365A (en)	1988-12-05	1989-10-24	Schering Corporation	Intermediate compounds for preparing penems and carbapenems
FR2640621B1 (fr)	1988-12-19	1992-10-30	Centre Nat Rech Scient	N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US4983597A (en)	1989-08-31	1991-01-08	Merck & Co., Inc.	Beta-lactams as anticholesterolemic agents
US5120729A (en)	1990-06-20	1992-06-09	Merck & Co., Inc.	Beta-lactams as antihypercholesterolemics
IL99658A0 (en)	1990-10-15	1992-08-18	Merck & Co Inc	Substituted azetidinones and pharmaceutical compositions containing them
JPH04356195A (ja)	1991-05-30	1992-12-09	Kyowa Hakko Kogyo Co Ltd	アゼチジノン誘導体の製造法
US5688785A (en)	1991-07-23	1997-11-18	Schering Corporation	Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688787A (en)	1991-07-23	1997-11-18	Schering Corporation	Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
IL102582A0 (en)	1991-07-23	1993-01-14	Schering Corp	Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5561227A (en)	1991-07-23	1996-10-01	Schering Corporation	Process for the stereospecific synthesis of azetidinones
LT3300B (en)	1992-12-23	1995-06-26	Schering Corp	Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en)	1993-01-21	1995-12-27	Schering Corp	Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
PL312502A1 (en)	1993-07-09	1996-04-29	Schering Corp	Method of manufacturing azetidinones
US5631365A (en)	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en)	1994-03-25	1997-05-06	Schering Corporation	Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en)	1994-11-18	1997-05-27	Schering Corporation	Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en)	1994-11-18	1997-04-29	Schering Corporation	Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en)	1994-12-21	1997-08-12	Schering Corporation	4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5631635A (en) *	1995-05-08	1997-05-20	Motorola, Inc.	Message/response tracking system and method for a two-way selective call receiving device
US5618707A (en)	1996-01-04	1997-04-08	Schering Corporation	Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
KR100311554B1 (ko)	1995-10-31	2002-06-20	둘락 노먼 씨.	콜레스테롤저하제로유용한슈가-치환된2-아제티디논
AU7472896A (en)	1995-11-02	1997-05-22	Schering Corporation	Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
WO1997021676A1 (en)	1995-12-08	1997-06-19	Smithkline Beecham Plc	Azetidinone compounds for the treatment of atherosclerosis
IL126696A0 (en)	1996-04-26	1999-08-17	Smithkline Beecham Plc	Azetidinone derivatives for the treatment of atherosclerosis
US5886171A (en)	1996-05-31	1999-03-23	Schering Corporation	3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en)	1996-05-31	1998-04-14	Schering Corporation	3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
GB9611947D0 (en)	1996-06-07	1996-08-07	Glaxo Group Ltd	Medicaments
WO1998001116A1 (en)	1996-07-09	1998-01-15	Merck & Co., Inc.	Therapy for combined hyperlipidemia
AU4050797A (en)	1996-08-02	1998-02-25	Ligand Pharmaceuticals Incorporated	Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
CA2266629C (en)	1996-10-01	2002-04-16	Cima Labs Inc.	Taste-masked microcapsule compositions and methods of manufacture
US5756470A (en)	1996-10-29	1998-05-26	Schering Corporation	Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
FR2758461A1 (fr)	1997-01-17	1998-07-24	Pharma Pass	Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
JP2001519329A (ja)	1997-10-07	2001-10-23	ベーリンガーインゲルハイム（カナダ）リミテッド	Ｈｃｍｖ感染症の治療用のアゼチジノン誘導体
US6133001A (en)	1998-02-23	2000-10-17	Schering Corporation	Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en)	1998-10-02	1999-07-06	Schering Corporation	Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
ATE297892T1 (de)	1998-12-07	2005-07-15	Schering Corp	Verfahren zur herstellung von azetidinonen
US6207822B1 (en)	1998-12-07	2001-03-27	Schering Corporation	Process for the synthesis of azetidinones
HK1042115A1 (zh)	1999-04-05	2002-08-02	Merck Sharp & Dohme Corp.	配製1-(4-氟苯)-3(r)-[3(s)-氟氧基-3-(4-氟苯)丙基)]-4(s)-(4-羥苯基)-2-azetidinone的立體定向微生物降低法
WO2000063703A1 (en)	1999-04-16	2000-10-26	Schering Corporation	Use of azetidinone compounds
PE20020718A1 (es)	2000-12-20	2002-08-09	Schering Corp	2-azetidinonas sustituidas con azucares utiles como agentes hipocolesterolemicos
KR100833089B1 (ko)	2000-12-21	2008-05-29	사노피-아벤티스 도이칠란트 게엠베하	신규한 1,2-디페닐아제티딘온 및 당해 화합물을 함유하는 지질 대사 장애를 치료하기 위한 약제학적 조성물
TWI291957B (en)	2001-02-23	2008-01-01	Kotobuki Pharmaceutical Co Ltd	Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same

2002
- 2002-03-25 CN CNB028075374A patent/CN1275949C/zh not_active Expired - Lifetime
- 2002-03-25 EE EEP200300464A patent/EE05453B1/et unknown
- 2002-03-25 EA EA200300970A patent/EA006898B1/ru not_active IP Right Cessation
- 2002-03-25 CA CA002442219A patent/CA2442219C/en not_active Expired - Lifetime
- 2002-03-25 UA UA2003109666A patent/UA75644C2/uk unknown
- 2002-03-25 AT AT02728561T patent/ATE305459T1/de active
- 2002-03-25 ES ES02728561T patent/ES2245733T3/es not_active Expired - Lifetime
- 2002-03-25 WO PCT/US2002/009123 patent/WO2002079174A2/en not_active Ceased
- 2002-03-25 CZ CZ2003-2610A patent/CZ304929B6/cs not_active IP Right Cessation
- 2002-03-25 HR HR20030760A patent/HRP20030760B1/xx not_active IP Right Cessation
- 2002-03-25 EP EP02728561A patent/EP1373230B1/en not_active Expired - Lifetime
- 2002-03-25 AU AU2002258605A patent/AU2002258605B2/en not_active Expired
- 2002-03-25 BR BRPI0208384A patent/BRPI0208384B1/pt active IP Right Grant
- 2002-03-25 MX MXPA03008803A patent/MXPA03008803A/es active IP Right Grant
- 2002-03-25 SK SK1186-2003A patent/SK287408B6/sk unknown
- 2002-03-25 NZ NZ527852A patent/NZ527852A/en not_active IP Right Cessation
- 2002-03-25 US US10/105,710 patent/US6627757B2/en not_active Expired - Lifetime
- 2002-03-25 DK DK02728561T patent/DK1373230T3/da active
- 2002-03-25 HU HU0303526A patent/HU230229B1/hu unknown
- 2002-03-25 DE DE60206365T patent/DE60206365T2/de not_active Expired - Lifetime
- 2002-03-25 IL IL15755202A patent/IL157552A0/xx unknown
- 2002-03-25 SI SI200230193T patent/SI1373230T1/sl unknown
- 2002-03-25 RS YUP-748/03A patent/RS50386B/sr unknown
- 2002-03-25 JP JP2002577801A patent/JP4145663B2/ja not_active Expired - Lifetime
- 2002-03-25 PL PL363864A patent/PL205952B1/pl unknown
- 2002-03-25 KR KR1020037012486A patent/KR100590342B1/ko not_active Expired - Lifetime
2003
- 2003-08-24 IL IL157552A patent/IL157552A/en unknown
- 2003-08-25 ZA ZA200306612A patent/ZA200306612B/en unknown
- 2003-09-09 BG BG108168A patent/BG66189B1/bg unknown

Also Published As

Publication number	Publication date
KR20030085573A (ko)	2003-11-05
CN1500083A (zh)	2004-05-26
BR0208384A (pt)	2004-06-15
MXPA03008803A (es)	2004-02-18
SK11862003A3 (sk)	2004-04-06
US6627757B2 (en)	2003-09-30
YU74803A (sh)	2006-05-25
PL363864A1 (en)	2004-11-29
CA2442219A1 (en)	2002-10-10
DK1373230T3 (da)	2005-11-07
CN1275949C (zh)	2006-09-20
NZ527852A (en)	2005-03-24
ES2245733T3 (es)	2006-01-16
HRP20030760A2 (en)	2004-08-31
ZA200306612B (en)	2004-10-12
SK287408B6 (sk)	2010-09-07
BG66189B1 (bg)	2011-12-30
HRP20030760B1 (hr)	2011-07-31
WO2002079174A3 (en)	2003-02-27
AU2002258605B2 (en)	2006-01-12
DE60206365T2 (de)	2006-07-06
PL205952B1 (pl)	2010-06-30
UA75644C2 (en)	2006-05-15
CA2442219C (en)	2007-09-11
JP2004532210A (ja)	2004-10-21
HU230229B1 (hu)	2015-10-28
EA006898B1 (ru)	2006-04-28
HK1057546A1 (en)	2004-04-08
SI1373230T1 (sl)	2005-12-31
BG108168A (en)	2004-09-30
US20020193607A1 (en)	2002-12-19
CZ20032610A3 (en)	2004-03-17
EP1373230A2 (en)	2004-01-02
JP4145663B2 (ja)	2008-09-03
IL157552A (en)	2009-08-03
EP1373230B1 (en)	2005-09-28
IL157552A0 (en)	2004-03-28
EA200300970A1 (ru)	2004-04-29
HUP0303526A2 (hu)	2004-01-28
KR100590342B1 (ko)	2006-06-15
BRPI0208384B1 (pt)	2016-05-31
WO2002079174A2 (en)	2002-10-10
DE60206365D1 (de)	2005-11-03
CZ304929B6 (cs)	2015-01-28
RS50386B (sr)	2009-12-31
EE05453B1 (et)	2011-08-15
ATE305459T1 (de)	2005-10-15
HUP0303526A3 (en)	2004-11-29

Publication	Publication Date	Title
EE200300464A (et)	2003-12-15	Protsess asetidinoonvaheühendite valmistamiseks ja asetidinoonvaheühend
ATE297203T1 (de)	2005-06-15	Antithrombotische mitteln
ATE306261T1 (de)	2005-10-15	Antithrombosemittel
MXPA04001323A (es)	2004-05-20	Dihidro-3-halo-1h-pirazol-5-carboxilatos sustituidos, su preparacion y uso.
BG106340A (en)	2002-10-31	Substituted oxoazaheterocyclyl compounds
NZ514711A (en)	2004-02-27	Compounds useful as anti-inflammatory agents
DE69931393D1 (de)	2006-06-22	Antithrombotische amide
AU2001280438A1 (en)	2002-02-13	Substituted heterocyclic amides
GB0127903D0 (en)	2002-01-16	Improvements relating to organic compounds
MY136269A (en)	2008-09-30	Novel diphenylazetidinone, process for its preparation, medicaments comprising this compound and their use
MY138263A (en)	2009-05-29	Therapeutic chroman compounds
ZA200404752B (en)	2005-04-26	6-aminomorphinane derivatives method for the production and use thereof
EP1656127A4 (en)	2009-04-29	COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
ATE308540T1 (de)	2005-11-15	Antithrombosemittel
MY139228A (en)	2009-08-28	Imidazolinylmethyl aralkylsulfonamides
MXPA03002493A (es)	2004-09-10	Proceso eficiente para preparacion de un inhibidor del factor xa.
MXPA04005151A (es)	2004-08-11	Compuestos terapeuticos.
NO20033049L (no)	2003-08-18	Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1-metylpiperidin
DE60230652D1 (de)	2009-02-12	Arylsulfanyl und heteroarylsulfanyl-derivate zur behandlung von schmerz
DE60043228D1 (de)	2009-12-10	Herstellungsverfahren von 2-cyanopyridinen
YU62302A (sh)	2005-03-15	Postupak za izradu jedinjenja 2-(4-alkil-1-piperazinil)- benzaldehida i benzilidenila

Legal Events

Date	Code	Title	Description
2012-10-15	HC1A	Change of owner name
2023-07-17	HC1A	Change of owner name